| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 83858-0105-30 | 83858-0105 | Dasatinib | PHYRAGO | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 1, 2024 | In Use | |
| 45629-0134-01 | 45629-0134 | Tivozanib | FOTIVDA | 1.34 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Mar 10, 2021 | In Use | |
| 00002-6902-30 | 00002-6902 | Pirtobrutinib | JAYPIRCA | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Jan 27, 2023 | In Use | |
| 66993-0237-30 | 66993-0237 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 3, 2024 | In Use | |
| 73207-0101-31 | 73207-0101 | Ripretinib | QINLOCK | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | KIT, PDGFRA | Oral | May 15, 2020 | In Use | |
| 69097-0031-91 | 69097-0031 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 18, 2025 | In Use | |
| 57962-0420-28 | 57962-0420 | Ibrutinib | IMBRUVICA | 420.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Feb 16, 2018 | In Use | |
| 00078-1098-94 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct 29, 2021 | In Use | |
| 00310-0512-60 | 00310-0512 | Acalabrutinib | Calquence | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Oct 31, 2017 | In Use | |
| 70771-1523-09 | 70771-1523 | Erlotinib | Erlotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
| 00310-0512-95 | 00310-0512 | Acalabrutinib | Calquence | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Apr 1, 2020 | Jul 31, 2025 | In Use |
| 59651-0546-15 | 59651-0546 | DASATINIB | DASATINIB | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
| 59651-0531-10 | 59651-0531 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jun 22, 2022 | In Use | |
| 00002-7026-99 | 00002-7026 | Pirtobrutinib | JAYPIRCA | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Feb 15, 2023 | In Use | |
| 57962-0420-71 | 57962-0420 | Ibrutinib | IMBRUVICA | 420.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Feb 6, 2019 | Dec 31, 2020 | In Use |
| 50742-0366-30 | 50742-0366 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 27, 2023 | In Use | |
| 43598-0458-36 | 43598-0458 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF | Oral | Jun 8, 2022 | In Use | |
| 72482-0100-12 | 72482-0100 | Pacritinib | Vonjo | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | JAK2, FLT3 | Oral | Feb 28, 2022 | In Use | |
| 62332-0565-90 | 62332-0565 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
| 50242-0092-86 | 50242-0092 | ENTRECTINIB | Rozlytrek | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug 15, 2019 | No Longer Used | |
| 00469-1425-21 | 00469-1425 | Gilteritinib | Xospata | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | Apr 30, 2022 | In Use | |
| 13668-0682-12 | 13668-0682 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Apr 12, 2023 | In Use | |
| 68001-0664-04 | 68001-0664 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 29, 2025 | In Use | |
| 63539-0044-01 | 63539-0044 | Axitinib | Inlyta | 5.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan 27, 2012 | In Use | |
| 43598-0046-63 | 43598-0046 | SUNITINIB MALATE | SUNITINIB MALATE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Nov 30, 2022 | In Use |
Found 12250 results — Export these results
Home